Age but not diagnosis is the main predictor of plasma amyloid β-protein levels

Archives of Neurology

Volumn 60, Issue 7, 2003, Pages 958-964

  Fukumoto, Hiroaki ^b   Tennis, Marsha ^b   Locascio, Joseph J ^b   Hyman, Bradley T ^b   Growdon, John H ^b   Irizarry, Michael C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; ESTROGEN; HORSERADISH PEROXIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN ANTIBODY;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NEUROLOGIC EXAMINATION; ONSET AGE; OUTPATIENT DEPARTMENT; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGE FACTORS; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 0037699792     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.60.7.958     Document Type: Article

References (40)

1. Walter J, Kaether C, Steiner H, Haass C. The cell biology of Alzheimer's disease: uncovering the secrets of secretases. Curr Opin Neurobiol. 2001;11:585-590.
2. Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (Aβ) in Alzheimer's disease brain. J Biol Chem. 1995;270:7013-7016.
3. Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y. Amyloid beta protein (Aβ) deposition. Ann Neurol. 1995;37:294-299.
4. Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci. 1997;148:41-45.
5. (1-42) In Alzheimer disease. Arch Neurol. 1999;56:673-680.
6. Galasko D, Chang L, Motter R, et al. High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937-945.
7. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643-648.
8. Nitsch RM, Rebeck GW, Deng M, et al. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease. Ann Neurol. 1995;37:512-518.
9. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med. 1996;2:864-870.
10. Kosaka T, Imagawa M, Seki K, et al. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at Aβ42(43). Neurology. 1997;48:741-745.
11. Mayeux R, Tang MX, Jacobs DM, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol. 1999;46:412-416.
12. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol. 2000;57:100-105.
13. Tamaoka A, Fukushima T, Sawamura N, et al. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J Neurol Sci. 1996;141:65-68.
14. Vanderstichele H, Van Kerschaver E, Hesse C, et al. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000;7:245-258.
15. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease. Neurology. 1984;34:939-944.
16. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Neurology. 2001;56:1133-1142.
17. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile change in the cerebral gray matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
18. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
19. Hoehn MM, Yahr MD. Parkinsonism. Neurology. 1967;17:427-442.
20. Fukumoto H, Tomita T, Matsunaga H, Ishibashi Y, Saido TC, Iwatsubo T. Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid beta peptides ending at Aβ40 and Aβ42. Neuroreport. 1999;10:2965-2969.
21. Kuo YM, Kokjohn TA, Kalback W, et al. Amyloid-beta peptides interact with plasma proteins and erythrocytes. Biochem Biophys Res Commun. 2000;268:750-756.
22. Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Consensus report of the Working Group on "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging. 1998;19:109-116.
23. Schupf N, Patel B, Silverman W, et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett. 2001;301:199-203.
24. Younkin SG, Eckman CB, Ertekin-Taner N, et al. Genetic elevation of plasma amyloid β protein in typical late onset Alzheimer's disease [abstract]. Abstr Soc Neurosci. 1998;24:263.
25. Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science. 2000;290:2303-2304.
26. Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees. Genet Epidemiol. 2001;21:19-30.
27. Tokuda T, Tamaoka A, Matsuno S, et al. Plasma levels of amyloid beta proteins did not differ between subjects taking statins and those not taking statins. Ann Neurol. 2001;49:546-547.
28. Fassbender K, Stroick M, Bertsch T, et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 2002;59:1257-1258.
29. Buxbaum JD, Cullen EI, Friedhoff LT. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovastatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front Biosci. 2002;7:a5-a59.
30. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol. 2002;52:346-350.
31. Irizarry MC, Hyman BT. Alzheimer disease therapeutics. J Neuropathol Exp Neurol. 2001;60:923-928.
32. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature. 2001;414:212-216.
33. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
34. Kawarabayashi T, Younkin LH, Saldo TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372-381.
35. Ghersi-Egea JF, Gorevic PD, Ghiso J, Frangione B, Patlak CS, Fenstermacher JD. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem. 1996;67:880-883.
36. Maness LM, Banks WA, Podlisny MB, Selkoe DJ, Kastin AJ. Passage of human amyloid beta-protein 1-40 across the murine blood-brain barrier. Life Sci. 1994;55:1643-1650.
37. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264-2267.
38. Mehta PD, Pirttila T, Patrick BA, Barshatzky M, Mehta SP. Amyloid beta protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett. 2001;304:102-106.
39. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun. 1995;213:96-103.
40. Graff-Radford N, Ertekin-Taner N, Jadeja N, Younkin L, Younkin S. Evidence that plasma amyloid beta protein may be useful as a premorbid biomarker for Alzheimer's disease [abstract]. Neurobiol Aging. 2002;23:S384.